PKP2-ACM
Clinical trials for PKP2-ACM explained in plain language.
Never miss a new study
Get alerted when new PKP2-ACM trials appear
Sign up with your email to follow new studies for PKP2-ACM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Gene therapy for rare heart disease passes early safety check
Disease control ENROLLING_BY_INVITATIONThis study follows 10 people who already received LX2020 gene therapy for arrhythmogenic cardiomyopathy caused by a PKP2 gene mutation. Researchers will monitor them for years to see if the treatment remains safe and continues to help control the disease. The goal is to understan…
Matched conditions: PKP2-ACM
Sponsor: Lexeo Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Gene therapy trial targets rare heart disease in 10 patients
Disease control OngoingThis early-stage trial tests a gene therapy called LX2020 for people with a heart condition called arrhythmogenic cardiomyopathy, caused by a change in the PKP2 gene. The study involves 10 adults who already have a defibrillator implanted. The main goal is to see if the treatment…
Matched conditions: PKP2-ACM
Phase: PHASE1, PHASE2 • Sponsor: Lexeo Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC